Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. One development candidate is TELINTRA® (TLK199) which is currently in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia. TELINTRA® is also being evaluated for the treatment of additional blood disorders. Another product candidate, TELCYTA® (TLK286), is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase 2 and Phase 3 clinical trials in advanced ovarian cancer, non-small cell lung cancer, colon cancer and breast cancer. These product candidates, and the other candidates in our pipeline, were discovered using our proprietary technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
2009 Annual Report
2010 Proxy Statement
13th Annual BIO CEO & Investor Conference
February 15, 2011
3:30 pm EDT (12:30 pm PDT)
Click here for the webcast.
February 08, 2011
Telik Announces Presentation and Webcast at 13th Annual BIO CEO & Investor Conference
December 06, 2010
Telik Announces Final Positive Phase 2 Results of a Multicenter Study of Oral Ezatiostat Hydrocloride (TELINTRA®, TLK199) in Patients with Myelodysplastic Syndrome